Literature DB >> 27392425

Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.

Ju Dong Yang1, Bashar A Aqel2, Surakit Pungpapong3, Gregory J Gores1, Lewis R Roberts1, Michael D Leise4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27392425     DOI： 10.1016/j.jhep.2016.06.023

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  55 in total

Review 1.  Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate.

Authors:  Kimberly E Daniel; Adnan Said
Journal:  Curr Gastroenterol Rep       Date:  2018-04-05

Review 2.  Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.

Authors:  Wei Zhang; Bixiang Zhang; Xiao-Ping Chen
Journal:  Front Med       Date:  2021-03-23       Impact factor: 4.592

3.  The Possible Association Between DAA Treatment for HCV Infection and HCC Recurrence.

Authors:  Brown Robert S
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-12

Review 4.  Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Authors:  Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2017-02-06

5.  Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC.

Authors:  Josep M Llovet; Augusto Villanueva
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

6.  Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma.

Authors:  Xavier Adhoute; Paul Castellani; Marc Bourlière
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-18

7.  Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.

Authors:  Winnie Y Zou; Kati Choi; Jennifer R Kramer; Xian Yu; Yumei Cao; Hashem B El-Serag; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2019-04-30       Impact factor: 3.199

8.  Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States.

Authors:  Ju Dong Yang; Joseph J Larson; Kymberly D Watt; Alina M Allen; Russell H Wiesner; Gregory J Gores; Lewis R Roberts; Julie A Heimbach; Michael D Leise
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-21       Impact factor: 11.382

9.  Occurrence and Recurrence of Hepatocellular Carcinoma After Successful Direct-Acting Antiviral Therapy for Patients With Chronic Hepatitis C Virus Infection.

Authors:  Sirisha Grandhe; Catherine T Frenette
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

10.  No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.

Authors:  Elijah J Mun; Pamela Green; Kristin Berry; George N Ioannou
Journal:  Eur J Gastroenterol Hepatol       Date:  2019-01       Impact factor: 2.566
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.